Business
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
About this update from Everest Medicines Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1650,"height":473,"url":"https://media.zenfs.com/en/business-wire.com/77690e00cbe969005d6e896a213341d7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BLgQh7k1bQw341OKPPE7Kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3NQ--/https://media.zenfs.com/en/business-wire.com/77690e00cbe969005d6e896a213341d7","width":960,"height":275},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/WxpRs_P_W5oCBE3PFPsQgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02ODg-/https://media.zenfs.com/en/business-wire.com/77690e00cbe969005d6e896a213341d7","width":1200,"height":344}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1650,"height":323,"url":"https://media.zenfs.com/en/business-wire.com/1f5eeecac1f5a0734c9f05bb6a69ec9e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t9uw4MVGhg949qvFIQ2.aQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4OA--/https://media.zenfs.com/en/business-wire.com/1f5eeecac1f5a0734c9f05bb6a69ec9e","width":960,"height":188},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lxIylD2We0_IG9xY7PCbhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NzA-/https://media.zenfs.com/en/business-wire.com/1f5eeecac1f5a0734c9f05bb6a69ec9e","width":1200,"height":235}}},{"type":"text","content":"ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the "Merger Agreement") to acquire Kezar Life Sciences, Inc. (NASDAQ: KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proceeds relating to Kezar’s collaboration with Everest Medicines and Kezar’s sale of its Sec61‑based d...